Olezarsen (Tryngolza) severe hypertriglyceridemia sNDA preview: first therapy to reduce pancreatitis risk in 3 million US adults

On June 30, 2026, the FDA is expected to decide on Ionis Pharmaceuticals' supplemental New Drug Application (sNDA) for olezarsen (marketed as Tryngolza) for the treatment of severe hypertriglyceridemia (sHTG). Already approved since December 2024 for familial chylomicronemia syndrome (FCS) — a rare genetic disorder affecting approximately 3,000 Americans — olezarsen is now poised to reach a far larger population: an estimated 3 million US adults with fasting triglyceride levels of 500 mg/dL or higher who are at elevated risk for acute pancreatitis.

The sNDA was accepted under Priority Review in February 2026, and olezarsen holds Breakthrough Therapy Designation for sHTG. The application is supported by two phase 3 pivotal trials, CORE and CORE2, both of which met their primary endpoints. If approved, olezarsen would be the first therapy proven to reduce the risk of acute pancreatitis attacks in patients with severe hypertriglyceridemia.

For payer organizations, specialty pharmacy operators, and market access teams, the potential approval of olezarsen in sHTG represents a new high-cost specialty drug category with a patient population orders of magnitude larger than the ultra-rare FCS indication. This preview covers the evidence, competitive landscape, pricing considerations, and what access teams should be preparing.

Short answer

The clinical need: severe hypertriglyceridemia and pancreatitis

Severe hypertriglyceridemia — defined as fasting triglyceride levels of 500 mg/dL or higher — affects an estimated 3 million adults in the United States. The most dangerous complication is acute pancreatitis, which carries a mortality rate of approximately 3–5% and is the leading cause of pancreatitis-related hospitalizations after gallstones and alcohol.

Current treatment options for sHTG are limited:

• Fibrates (fenofibrate, gemfibrozil) modestly reduce triglycerides but have not demonstrated reduction in pancreatitis risk in dedicated outcomes trials
• Prescription omega-3 fatty acids (icosapent ethyl, Vascepa) reduce cardiovascular risk in statin-treated patients with elevated triglycerides but are not specifically indicated for pancreatitis prevention in sHTG
• Diet and lifestyle modifications are universally recommended but insufficient for many patients
• No approved therapy has demonstrated a reduction in acute pancreatitis events in the sHTG population

This evidence gap is precisely what the FDA's Breakthrough Therapy Designation recognizes: olezarsen has the potential to address a serious unmet medical need.

How olezarsen works

Olezarsen is an RNA-targeted Ligand Conjugated Antisense (LICA) medicine. It binds to apolipoprotein C-III (apoC-III) mRNA in the liver, reducing the production of apoC-III protein. ApoC-III is a key regulator of triglyceride metabolism — it inhibits lipoprotein lipase (LPL) activity and impairs the hepatic uptake of triglyceride-rich lipoprotein remnants.

By suppressing apoC-III production, olezarsen:

1. Enhances LPL activity, accelerating the clearance of triglyceride-rich chylomicrons and VLDL particles
2. Reduces serum apoC-III protein levels, removing the inhibitory brake on triglyceride metabolism
3. Lowers fasting triglyceride levels and, critically, reduces the risk of acute pancreatitis events

The drug is administered as a subcutaneous injection once monthly, making it suitable for self-administration or specialty pharmacy distribution.

CORE and CORE2: the pivotal phase 3 trials

Ionis' sNDA is supported by two phase 3 randomized, double-blind, placebo-controlled trials:

CORE (NCT05079919)

• Design: Randomized, double-blind, placebo-controlled trial in adults with sHTG (fasting TG ≥ 500 mg/dL)
• Arms: Olezarsen 80 mg monthly subcutaneously vs placebo
• Primary endpoint: Percent change in fasting triglycerides from baseline to month 6
• Result: Statistically significant placebo-adjusted reduction of 72% in fasting triglycerides
• Secondary endpoint: 85% reduction in the risk of acute pancreatitis events after one year of treatment
• Safety: Favorable safety and tolerability profile

CORE2 (NCT05552326)

• Design: Confirmatory phase 3 trial with similar design to CORE
• Primary endpoint: Met with statistical significance
• Result: Placebo-adjusted reduction of 55% in fasting triglycerides
• Pooled analysis: Across both trials, over 85% of patients on the 80 mg dose achieved triglyceride levels below the 500 mg/dL risk threshold

Results were published in the New England Journal of Medicine and presented at the American Heart Association scientific sessions. A pooled subgroup analysis presented at the 2026 EAS Congress further showed that patients with the highest baseline triglyceride levels (≥ 10 mmol/L, approximately 886 mg/dL) experienced a 66% placebo-adjusted reduction at six months, demonstrating consistent efficacy across disease severity.

Real-world context

Global acute pancreatitis cases increased 59% between 1990 and 2021, with deaths rising 78.7% over the same period, according to a study published in BMC Gastroenterology. The growing burden underscores the clinical need for effective triglyceride-lowering therapies that can prevent pancreatitis attacks.

Pricing and market considerations

FCS pricing as a reference point

Tryngolza launched in the US in early 2025 for FCS at a wholesale acquisition cost (WAC) of $595,000 per year — consistent with other ultra-rare disease therapies. Ionis reported $108 million in net product sales for Tryngolza in 2025, exceeding expectations for the FCS launch.

For sHTG, the pricing calculus is fundamentally different. With a potential patient population of 3 million — a thousand times larger than FCS — Ionis faces the challenge of pricing a specialty drug for a broad chronic disease population.

Pricing: Ionis sets $40,000 WAC for both FCS and sHTG

In March 2026, Ionis dramatically reduced Tryngolza's WAC from $595,000 to $40,000 per year, effective April 1, 2026 — ahead of the anticipated sHTG approval. The new price applies to both the existing FCS indication and the potential sHTG indication. Ionis said the price reflects "the substantial value that olezarsen can provide to patients, healthcare professionals and the healthcare system, while supporting timely and sustained patient access," and was set following extensive payer and physician research.

At $40,000 WAC, Ionis expects a net price above its earlier assumed $10,000–$20,000 range, which led the company to raise its US peak sales guidance for olezarsen in sHTG to greater than $3 billion, up from greater than $2 billion.

Ionis has hired a field force of approximately 200 representatives to support the sHTG launch, signaling commercial readiness for a large-scale roll-out.

Competitive landscape: Arrowhead's plozasiran

Ionis is not alone in targeting the sHTG market. Arrowhead Pharmaceuticals is developing plozasiran (Redemplo), an siRNA-based therapy that also targets apoC-III. Plozasiran is also approved for FCS and is in late-stage development for sHTG.

The potential competition from plozasiran could influence pricing and payer negotiations. Both drugs target the same protein (apoC-III) through different mechanisms (antisense oligonucleotide vs siRNA), and comparative data is not yet available. Payers will likely position them in the same therapeutic class.

Access implications for payers and market access teams

Prior authorization criteria

If approved, payers are likely to impose prior authorization for olezarsen in sHTG. Oregon's Drug Use Research & Management program, which published a new drug evaluation for Tryngolza in February 2026, provides an early model for PA criteria that other payers may follow:

• Fasting triglyceride threshold: TG ≥ 500 mg/dL confirmed within the previous 6 months
• Failed prior therapy: Documentation of inadequate benefit with, or contraindication to, an adequate trial (at least 8 weeks) of a fibric acid derivative (fenofibrate or gemfibrozil)
• Dietary compliance: Attestation of adherence to a low-fat diet
• Prescriber specialty: Likely restricted to endocrinologists, cardiologists, gastroenterologists, or lipid specialists
• Initial authorization: 6 months
• Reauthorization: Documentation of positive clinical response (clinically meaningful reduction in triglyceride level or reduction in episodes of acute pancreatitis)

UnitedHealthcare's existing PA criteria for Tryngolza in FCS — which requires genetic confirmation or a clinical FCS score, fasting TG ≥ 880 mg/dL, and specialist prescribing — provides a template for the expected rigor of PA criteria in sHTG, though the sHTG criteria will use a lower TG threshold and different prior-therapy requirements.

Safety monitoring will also be a PA consideration. Clinical studies noted mild thrombocytopenia in some patients, and the Oregon review flagged elevated hepatic transaminases as a monitoring concern. Payers may require baseline and periodic platelet counts and liver function tests.

Formulary positioning

Olezarsen will likely be placed on the specialty tier (Tier 4 or 5) of commercial formularies and Medicare Part D formularies. Key considerations:

• Step therapy: Most payers will require trial and failure of a fibrate before approving olezarsen
• Specialty pharmacy distribution: Monthly subcutaneous injection requires specialty pharmacy fulfillment and patient support services
• Competitive exclusion: PBMs may eventually negotiate exclusive positioning between olezarsen and plozasiran once both are approved
• Medical vs pharmacy benefit: As a self-administered injectable, olezarsen will be managed under the pharmacy benefit

Medicare Part D considerations

Patients with sHTG who are Medicare Part D beneficiaries will face the standard Part D benefit design, including:

• The 2026 out-of-pocket cap of $2,100
• Specialty tier coinsurance (typically 25–33%) before reaching the catastrophic phase
• Potential application of the IRA's Medicare Drug Price Negotiation Program in future cycles, given the likely high expenditure if uptake is broad

Ionis patient support: Every Step program

Ionis has established the "Every Step" patient support program for Tryngolza in FCS, which provides:

• Benefit investigation and prior authorization support
• Copay assistance for commercially insured patients
• Patient education and nursing support for self-injection training

The program is expected to expand for the sHTG indication, though the copay assistance structure may differ given the larger population and different pricing.

What to watch

• June 30, 2026: PDUFA target action date for the olezarsen sHTG sNDA
• Labeling scope: Whether the FDA restricts the indication to specific triglyceride thresholds or pancreatitis history requirements
• Pricing announcement: Ionis set WAC at $40,000/year for both FCS and sHTG effective April 1, 2026 — payer negotiations will determine net price and access
• PBM formulary decisions: Watch for CVS Caremark, Express Scripts, and OptumRx positioning in their 2027 formulary updates
• Plozasiran competition: Arrowhead's regulatory timeline for plozasiran in sHTG will determine how quickly competitive pressure emerges
• Specialty pharmacy network: Ionis' distribution strategy for the sHTG population will affect access speed
• IRA negotiation eligibility: Olezarsen's total Medicare spending trajectory could make it a candidate for future IRA negotiation cycles

Sources

• Ionis Pharmaceuticals. "Olezarsen sNDA Accepted by the FDA for Priority Review for the Treatment of Severe Hypertriglyceridemia (sHTG)." February 26, 2026. https://ir.ionis.com/news-releases/news-release-details/olezarsen-snda-accepted-fda-priority-review-treatment-severe
• Ionis Pharmaceuticals. "Ionis Well-Positioned for Continued Momentum and Substantial Value Creation in 2026." January 2026. https://ir.ionis.com/news-releases/news-release-details/ionis-well-positioned-continued-momentum-and-substantial-value
• Fierce Pharma. "Ionis Doubles Its Sales Projection for Tryngolza in sHTG to $2B." January 13, 2026. https://www.fiercepharma.com/pharma/jpm26-ionis-bolstered-strong-launch-tryngolza-doubles-its-sales-projection-new-indication-2b
• Fierce Pharma. "Ionis Slashes Tryngolza's Price Tag Down Ahead of Anticipated Expansion Into Wider sHTG Market." March 25, 2026. https://www.fiercepharma.com/pharma/ionis-slashes-tryngolzas-price-tag-down-ahead-anticipated-expansion-wider-shtg-market
• ClinicalTrials.gov. "A Study of Olezarsen Administered to Participants with Severe Hypertriglyceridemia." NCT05079919. https://clinicaltrials.gov/ct2/show/NCT05079919
• ClinicalTrials.gov. "A Study of Olezarsen (ISIS 678354) Administered to Participants with Severe Hypertriglyceridemia." NCT05552326. https://clinicaltrials.gov/ct2/show/NCT05552326
• Stroes ESG, Alexander VJ, et al. "Olezarsen, Acute Pancreatitis, and Familial Chylomicronemia Syndrome." New England Journal of Medicine. 2024;390:1781-1792. https://pubmed.ncbi.nlm.nih.gov
• Drugs.com. "Tryngolza (Olezarsen) FDA Approval History." https://www.drugs.com/history/tryngolza.html
• Oregon State University Drug Use Research & Management Program. "New Drug Evaluation: Tryngolza (Olezarsen) Injection." February 2026. http://www.orpdl.org/durm/meetings/meetingdocs/2026_02_05/drafts/Tryngolza_NDE.pdf
• UnitedHealthcare. "Prior Authorization/Medical Necessity — Tryngolza (Olezarsen)." https://www.uhcprovider.com/content/dam/provider/docs/public/prior-auth/drugs-pharmacy/commercial/r-z/PA-Med-Nec-Tryngolza.pdf
• TRYNGOLZA Prescribing Information. Ionis Pharmaceuticals. https://tryngolzahcp.com